search
Back to results

Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma (LND for ICC)

Primary Purpose

Intrahepatic Cholangiocarcinoma

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
lymphadenectomy
Sponsored by
First Affiliated Hospital Xi'an Jiaotong University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Intrahepatic Cholangiocarcinoma focused on measuring intrahepatic cholangiocarcinoma, surgery, lymphadenectomy, lymph node metastasis, prognosis

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients diagnosed with intrahepatic cholangiocarcinoma by imaging or biopsy
  • The tumor is limited in the liver with no distant metastasis, and the primary disease is resectable
  • Preoperative imaging (e.g. CT, MRI, PET-CT, etc.) and intraoperative exploration found no nodal swelling or enlargement

Exclusion Criteria:

  • The primary disease is unresectable with or without distant metastasis
  • The liver function or general condition of patients does not permit surgery
  • Preoperative imaging (e.g. CT, MRI, PET-CT, etc.) and intraoperative exploration found obvious nodal swelling or enlargement, which indicates lymphadenectomy should be performed
  • Patients aged below 18 or older than 65 would be excluded
  • Pregnant women would not be enrolled

Sites / Locations

  • The First Affiliated Hospital of Xi'an Jiaotong University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

lymphadenectomy

No lymphadenectomy

Arm Description

This group of patients would undergo routine hepatoduodenal lymphadenectomy combined with ICC resection

This group of patients would not undergo hepatoduodenal lymphadenectomy when preoperative imaging and intraoperative exploration found no lymph node enlargement.

Outcomes

Primary Outcome Measures

1-year recurrence rate
compare the 1-year recurrence rate of patients undergoing lymphadenectomy and those not undergoing lymphadenectomy
3-year recurrence rate
compare the 3-year recurrence rate of patients undergoing lymphadenectomy and those not undergoing lymphadenectomy

Secondary Outcome Measures

Postoperative morbidity
investigate the postoperative morbidity, such as hepatic failure, postoperative bleeding, superficial and deep site infection between lymphadenectomy and no lymphadenectomy groups
1-year overall survival
compare the 1-year overall survival rate of patients undergoing lymphadenectomy and those not undergoing lymphadenectomy
3-year overall survival
compare the 3-year overall survival rate of patients undergoing lymphadenectomy and those not undergoing lymphadenectomy

Full Information

First Posted
January 6, 2019
Last Updated
December 7, 2021
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Collaborators
Ningxia Medical University, Nanchang University, Binzhou Medical University, Shaanxi Provincial People's Hospital, Shaanxi University of Chinese Medicine, The Third Affiliated Hospital of Beijing University
search

1. Study Identification

Unique Protocol Identification Number
NCT03796819
Brief Title
Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma
Acronym
LND for ICC
Official Title
Impact of Routine Lymphadenectomy on Prognosis of Patients Undergoing Curative Resection for Intrahepatic Cholangiocarcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Completed
Study Start Date
January 10, 2019 (Actual)
Primary Completion Date
August 1, 2021 (Actual)
Study Completion Date
December 1, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Collaborators
Ningxia Medical University, Nanchang University, Binzhou Medical University, Shaanxi Provincial People's Hospital, Shaanxi University of Chinese Medicine, The Third Affiliated Hospital of Beijing University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The role of routine lymphadenectomy (LND) in the surgical treatment of intrahepatic cholangiocarcinoma (ICC) remains controversial. The investigators' multi-institutional retrospective study have showed an increasing adoption of LND among patients undergoing curative resection for ICC during the last decade. The current prospective and randomized study based on a multi-institutional collaboration would investigate whether routine LND would benefit patients in short- and long-term survival remains.
Detailed Description
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer and its incidence is increasing worldwide.Resection of the primary ICC tumor site within the liver represents the best curative treatment option. However, the role of lymphadenectomy (LND) at the time of surgery remains controversial with some centers considering it standard while other surgeons perform LND only in select circumstances. The utilization of LND may not only vary among different institutions, but also by geographic region. Specifically, data from East and West centers have noted a variation in the utilization of LND ranging 27%-100%.While several case series from Asia have noted that most centers do not regularly perform LND,other data from the West suggest that LND may be becoming more routine. Despite the lack of consensus among surgeons, the American Joint Committee on Cancer (AJCC) Staging manual recommends that the nodal basin be staged. Disease-specific staging for ICC was first introduced in the 7th edition of the AJCC staging manual published in 2010. The newly updated 8th edition of the AJCC staging system now recommends that 6 lymph nodes be evaluated to stage a patient with ICC. The previous multi-institutional retrospective study from the investigators have showed an increasing adoption of LND among patients undergoing curative resection for ICC during the last decade. The current prospective and randomized study based on a multi-institutional collaboration would investigate whether routine LND would benefit patients in short- and long-term survival remains.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intrahepatic Cholangiocarcinoma
Keywords
intrahepatic cholangiocarcinoma, surgery, lymphadenectomy, lymph node metastasis, prognosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
routine hepatoduodenal lymphadenectomy
Masking
ParticipantOutcomes Assessor
Masking Description
patients would not be told about the lymphadenectomy
Allocation
Randomized
Enrollment
260 (Actual)

8. Arms, Groups, and Interventions

Arm Title
lymphadenectomy
Arm Type
Experimental
Arm Description
This group of patients would undergo routine hepatoduodenal lymphadenectomy combined with ICC resection
Arm Title
No lymphadenectomy
Arm Type
No Intervention
Arm Description
This group of patients would not undergo hepatoduodenal lymphadenectomy when preoperative imaging and intraoperative exploration found no lymph node enlargement.
Intervention Type
Procedure
Intervention Name(s)
lymphadenectomy
Intervention Description
Patients would undergo routine hepatoduodenal lymphadenectomy at the time of ICC resection
Primary Outcome Measure Information:
Title
1-year recurrence rate
Description
compare the 1-year recurrence rate of patients undergoing lymphadenectomy and those not undergoing lymphadenectomy
Time Frame
1 year after surgery (up to 1 year)
Title
3-year recurrence rate
Description
compare the 3-year recurrence rate of patients undergoing lymphadenectomy and those not undergoing lymphadenectomy
Time Frame
3 years after surgery (up to 3 years)
Secondary Outcome Measure Information:
Title
Postoperative morbidity
Description
investigate the postoperative morbidity, such as hepatic failure, postoperative bleeding, superficial and deep site infection between lymphadenectomy and no lymphadenectomy groups
Time Frame
From the date of surgery to stitches off (up to 1 month)
Title
1-year overall survival
Description
compare the 1-year overall survival rate of patients undergoing lymphadenectomy and those not undergoing lymphadenectomy
Time Frame
1 year after surgery (up to 1 year)
Title
3-year overall survival
Description
compare the 3-year overall survival rate of patients undergoing lymphadenectomy and those not undergoing lymphadenectomy
Time Frame
3 years after surgery (up to 3 years)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with intrahepatic cholangiocarcinoma by imaging or biopsy The tumor is limited in the liver with no distant metastasis, and the primary disease is resectable Preoperative imaging (e.g. CT, MRI, PET-CT, etc.) and intraoperative exploration found no nodal swelling or enlargement Exclusion Criteria: The primary disease is unresectable with or without distant metastasis The liver function or general condition of patients does not permit surgery Preoperative imaging (e.g. CT, MRI, PET-CT, etc.) and intraoperative exploration found obvious nodal swelling or enlargement, which indicates lymphadenectomy should be performed Patients aged below 18 or older than 65 would be excluded Pregnant women would not be enrolled
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yi Lv, MD, PhD
Organizational Affiliation
First Affiliated Hospital Xi'an Jiaotong University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Xu-Feng Zhang, MD,PhD
Organizational Affiliation
First Affiliated Hospital Xi'an Jiaotong University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The First Affiliated Hospital of Xi'an Jiaotong University
City
Xi'an
State/Province
Shaanxi
ZIP/Postal Code
710061
Country
China

12. IPD Sharing Statement

Learn more about this trial

Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma

We'll reach out to this number within 24 hrs